Skip to main content
Clinical Trials/NCT03739944
NCT03739944
Unknown
Phase 3

Randomized Trial of Different Surgical Approaches in Patients of Chinese Early-stage Cervical Cancer

Lei Li1 site in 1 country700 target enrollmentNovember 23, 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Uterine Cervical Neoplasm
Sponsor
Lei Li
Enrollment
700
Locations
1
Primary Endpoint
Progression-free survival
Last Updated
7 years ago

Overview

Brief Summary

This multi-center, randomized controlled study aims to compare the survival outcomes (including overall survival, progression-free survival and disease-free survival between Chinese uterine cervical patients receiving different surgical routes (laparotomy and laparoscopy) for radical hysterectomy or trachelectomy, which is the primary study objective. All patients with uterine cervical cancer of FIGO stage IA1 (with lymphovascular space invasion), IA2 and IB1 will be included and randomized into two groups: laparotomy and laparoscopy groups for radical hysterectomy or trachelectomy. Secondary study objectives include: patterns of recurrence, treatment-associated morbidity (6 months from surgery), cost-effectiveness, pelvic floor function, and quality of life.

Registry
clinicaltrials.gov
Start Date
November 23, 2018
End Date
November 23, 2023
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Lei Li
Responsible Party
Sponsor Investigator
Principal Investigator

Lei Li

Professor

Peking Union Medical College Hospital

Eligibility Criteria

Inclusion Criteria

  • Confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix
  • FIGO stage IA1 (with lymphovascular space invasion), IA2 or IB1
  • Type II or III radical hysterectomy or trachelectomy
  • Performance status of ECOG 0-1
  • Aged 18 years or older
  • Signed an approved informed consents

Exclusion Criteria

  • Not satisfying any of the inclusion criteria

Outcomes

Primary Outcomes

Progression-free survival

Time Frame: Five years

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.

Secondary Outcomes

  • Morbidity rate(Six months)
  • Overall survival(Five years)
  • Disease-free survival(Five years)

Study Sites (1)

Loading locations...

Similar Trials